ArticleCancer immunology, immunotherapy : CII2010
Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.
Article in Cancer immunology, immunotherapy : CII, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2019Trial
- Determination of CAR T cell metabolism in an optimized protocol.Frontiers in bioengineering and biotechnology · 2023Article
- Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.Cancer immunology, immunotherapy : CII · 2015Article
- Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.Journal for immunotherapy of cancer · 2015Article
- Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining.Cancer immunology, immunotherapy : CII · 2014Article
- Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells.Clinical and vaccine immunology : CVI · 2014Article
- Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.Cancer immunology, immunotherapy : CII · 2013Article
- The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study.Cancer immunology, immunotherapy : CII · 2013Article
- Comparing and combining data across multiple sources via integration of paired-sample data to correct for measurement error.Statistics in medicine · 2012Article
- Harmonization of the intracellular cytokine staining assay.Cancer immunology, immunotherapy : CII · 2012Article
- The immuno-oncology framework: Enabling a new era of cancer therapy.Oncoimmunology · 2012Article
- Standardized Serum-Free Cryomedia Maintain Peripheral Blood Mononuclear Cell Viability, Recovery, and Antigen-Specific T-Cell Response Compared to Fetal Calf Serum-Based Medium.Biopreservation and biobanking · 2011Article
- Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Review
- ELISpot for measuring human immune responses to vaccines.Expert review of vaccines · 2011Review
- Response definition criteria for ELISPOT assays revisited.Cancer immunology, immunotherapy : CII · 2010Article
- Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.Cancer immunology, immunotherapy : CII · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The Cancer Immunotherapy Immunoguiding Program has conducted an IFN-gamma ELISPOT proficiency panel to examine the influence of serum supplementation of test media on assay performance. Sixteen European laboratories analyzed the same PBMC samples using different locally established protocols. Participants generated two simultaneous data sets-one using medium supplemented with serum and one without serum. Performances of the two test conditions were compared by quantifying: (1) the number of viable cells, (2) background spot formation induced in the medium only control and (3) the ability to detect antigen-specific T cell responses. The study demonstrated that the number of viable cells recovered and the overall background spot production were not significantly different between the two conditions. Furthermore, overall laboratory performance was equivalent for the two test conditions; 11 out of 16 laboratories reported equal or greater detection rates using serum-free medium, while 5 laboratories reported decreased detections rates under serum-free conditions. These results show that good performance of the IFN-gamma ELISPOT assay can be achieved under serum-free conditions. Optimization of the protocol for serum-free conditions should result in excellent detection rates and eliminate the requirement of serum batch and stability testing, allowing further harmonization of the assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.